2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Non-Biological Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bleeding and Clotting, Platelet Disorders, Genetic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult
PAPER

3834 Inflammasome modulation with ofirnoflast (HT-6184) normalizes the neutrophil-to-lymphocyte ratio and rescues lymphopoiesis in Ph2a clinical trial in lower risk-myelodysplastic syndrome patients

David Sallman, MD, Varun Bafna, MD, MBBS, DM2, Taylor Avei, MBA3, Rami Komrokji, MD4, Zhuoer Xie, MD,MS5, June Bearss6, Devan Bursey, MSc7, Jeremiah Bearss, MD, PhD8, David Bearss, PhD9, Han Myint, MD, FRCP, FRCPath10, Amit Verma, MD11
1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Utah, United States
2 Star Superspeciality Clinic and Hospital, Kolhapur, India, Kolhapur, India
3 Halia Therapeutics, Lehi, Utah, United States
4 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center and Research Institute, Tampa, Utah, United States
6 Halia Therapeutics, Lehi, Utah, United States
7 Halia Therapeutics, Lehi, Utah, United States
8 Halia Therapeutics, Lehi, Utah, United States
9 Halia Therapeutics, Lehi, Utah, United States
10 Halia Therapeutics, Lehi, Utah, United States
11 Albert Einstein College of Medicine, Bronx, New York, United States

Background The neutrophil-to-lymphocyte ratio (NLR), a marker of poor prognosis in cancer, reflects the relative balance between innate inflammatory activity and adaptive immune function. In myelodysplastic syndromes, an elevated NLR predicted inferior overall survival and inferior responses to therapy (Komrokji et al., ASH 2024). Ofirnoflast (HT-6184) is an oral, allosteric modulator of NEK7/NLRP3 inflammasome assembly, hypothesized to relieve innate immune myeloid inflammation in the dysplastic marrow. In a Phase 2a study, Ofirnoflast was given orally at 2mg 5 days on/ 2 days off in patients with lower risk-myelodysplastic syndrome(LR-MDS) and resulted in 55.6% of red blood cell(RBC) transfusion dependent patients achieving 8-week RBC-transfusion independence and 63.3% of patients achieving 8-week hematologic improvement-erythroid (HI-E) (Bafna V et al., EHA 2026). Building on these findings, we examined whether ofirnoflast alters NLR in LR-MDS and whether changes are driven by neutrophil or lymphocyte compartment. 

Methods We conducted an exploratory, post hoc analysis of peripheral-blood counts from the central laboratory in the Phase 2a HT-6184-MDS-001 study. This open-label, single-arm, Phase 2a trial enrolled adults with IPSS-R very low to intermediate-risk MDS (score <4.5) with symptomatic anemia (Hgb <9 g/dL) or RBC transfusion dependence who were ESA-refractory, intolerant, or ineligible. Ofirnoflast 2 mg was administered orally once daily (5 days on/2 days off) for up to 32 weeks. The primary endpoint was hematological improvement (HI) per IWG 2018 criteria. Absolute neutrophil count (ANC), absolute lymphocyte count (ALC), and NLR were evaluated at baseline and throughout treatment. For each patient, these were summarized as the median of on-treatment values, and group-level estimates as the median of per-patient medians. Patients were classified by HI-E response. Within-patient baseline-to-on-treatment changes were compared using the Wilcoxon signed-rank test; baseline differences between responders and non-responders by Mann–Whitney U test. The analytic population comprised 30 patients: 19 HI-E responders and 11 non-responders.

Results Baseline NLR was significantly higher in HI-E responders than in non-responders (median 3.4 vs. 1.45; mean 7.2 vs. 1.5; p=0.02), contrary to the conventional association of elevated NLR with inferior outcomes. The median ALC for responders was 0.8 ×10⁹/L (range 0.1–1.5), with 11/19 (57.9%) below 1.0 ×10⁹/L, versus the median ALC for non-responders being 1.53 ×10⁹/L (range 0.7–5.28), with only 4/11 (36.4%) below 1.0 ×10⁹/L. Baseline ANC was comparable between groups (responders median 2.39 ×10⁹/L, range 0.4-14.1; non-responders median 1.86 ×10⁹/L; range 0.9–5.5).

On treatment, responders showed a significant increase in ALC (median 0.8 to 1.4 ×10⁹/L; p = 0.0005) while ANC remained unchanged (median 2.39 to 2.56 ×10⁹/L; p = 0.44), resulting in a significant decline in NLR (median 3.4 to 1.9; p = 0.003). An increase in ALC from baseline during the on-treatment phase, was observed in 16/19 responders (84.2%). In contrast, non-responders showed stable lymphocyte counts (median ALC 1.53 to 1.62 ×10⁹/L; p = 0.52) while ANC rose (median 1.9 to 2.6 ×10⁹/L; p = 0.001), driving an increase in NLR (median 1.45 to 1.82; p = 0.001).

To explore whether this correlation was related to the mechanism of action of ofirnoflast, we evaluated the association between baseline NLR and response to approved treatment for LR_MDS patients treated at Moffitt Cancer Center. A modest association was observed between higher baseline NLR and response to ESAs (OR 1.04, 95% CI 1.00-1.08; p = 0.042; n = 1,512). In contrast, no significant association was identified between baseline NLR and response to luspatercept (OR 0.99, 95% CI 0.91-1.07; p = 0.80; n = 242) or imetelstat (OR 0.96, 95% CI 0.38-1.47; p = 0.78; n = 30) 

Conclusion A higher baseline NLR has been regarded as a marker of poor prognosis in many cancers including MDS patients. Here, a high NLR predicted HI-E response in patients with LR-MDS treated with ofirnoflast, which reduced NLR through lymphocyte recovery, consistent with the relief of inflammation-driven immunosuppression. These observations suggest baseline NLR may be a predictive patient-selection biomarker for treatment response warranting prospective validation, which will be performed in the upcoming multi-center Phase 2b study (NCT07738510).

David Sallman, MD: Jazz Pharmaceuticals and Aprea Therapeutics (institution) - Research Funding; AbbVie Inc, Bristol-Myers Squibb, Gilead Sciences, Kite (a Gilead company), Novartis, Syndax, Janssen, SERVIER, Syros Pharmaceuticals, Takeda, Molecular Partners, AvenCell, Agios, Dark Blue Therapeutics - Consultancy (Includes expert testimony)